Media Centre

7 April 2009

Serentis Starts Phase II Trial with First-in-Class SRD441 for Eczema

4 March 2009

Serentis Starts Phase II Clinical Trial with SRD174 in Pruritus of Skin Disease

24 February 2009

Serentis Appoints Dr Robert Tansley as Chief Medical Officer

12 August 2008
Serentis Announces New Investment to Advance Dermatology Pipeline

31 March 2008
Serentis Appoints Gunnar Staaf as Commercial Director

30 October 2007
Serentis Appoints Peter Keen as New Corporate Development and Finance Director

2 October 2007
Serentis Acquires Atopic Dermatitis Company Surface Therapeutics

3 July 2007
Serentis Raises £10.3 Million Series A Financing